Skip to main content
SpringerLink
Log in
Book cover

Angiogenesis Inhibition pp 165–183Cite as

Metronomic Chemotherapy: Principles and Lessons Learned from Applications in the Treatment of Metastatic Prostate Cancer

  • Chapter
  • First Online:

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 180))

Abstract

By frequent and protracted administration of conventional cytotoxic drugs without prolonged interruptions, the primary treatment target shifts from the tumor cell population to the tumor vasculature. This “metronomic” way of chemotherapy administration results in antivascular effects, the mechanistic basis of which remains to be fully elucidated. We outline the basic aspects of the metronomic concept, describe the results of clinical applications of such chemotherapy by focusing on studies in metastatic prostate cancer, and discuss certain shortcomings. Based on preclinical findings, we finally point to the possible ways to address these shortcomings in order to bring this novel and promising use of conventional anticancer agents to full fruition.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Bertolini F, Mancuso P, Shaked Y, Kerbel RS (2007) Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today 12:806–812

    Article  PubMed  CAS  Google Scholar 

  • Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342–4346

    PubMed  CAS  Google Scholar 

  • Bertolini F, Shaked Y, Mancuso P, Kerbel RS (2006) The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6:835–845

    Article  PubMed  CAS  Google Scholar 

  • Bocci G, Francia G, Man S, Lawler J, Kerbel RS (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 100: 12917–12922

    Article  PubMed  CAS  Google Scholar 

  • Bocci G, Nicolaou KC, Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62:6938–6943

    PubMed  CAS  Google Scholar 

  • Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, Del Tacca M (2005) Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 16:1243–1252

    Article  PubMed  CAS  Google Scholar 

  • Bolontrade MF, Zhou RR, Kleinerman ES (2002) Vasculogenesis plays a role in the growth of Ewing’s sarcoma in vivo. Clin Cancer Res 8: 3622–3627

    PubMed  Google Scholar 

  • Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, Dogliotti L, Berruti A (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24: 3623–3628

    Article  PubMed  CAS  Google Scholar 

  • Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886

    PubMed  CAS  Google Scholar 

  • Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M (2006) High-dose celecoxib and metronomic “low-dose” cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin’s lymphoma. Clin Cancer Res 12:5190–5198

    Article  PubMed  CAS  Google Scholar 

  • Burstein HJ, Spigel D, Kindsvogel K, Parker LM, Bunnel CA, Partridge AH, Come SE, Ryan PD, Gelman R, Winer EP (2005) Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. In: San Antonio Breast Cancer Symposium. Breast Cancer Res Treat 94(Suppl 1):S6, Abstract 4

    Google Scholar 

  • Casanova M, Ferrari A, Bisogno G, Merks JH, De Salvo GL, Meazza C, Tettoni K, Provenzi M, Mazzarino I, Carli M (2004) Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 101:1664–1671

    Article  PubMed  CAS  Google Scholar 

  • Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nole F, Viale G, Goldhirsch A (2006) Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 17: 232–238

    Article  PubMed  CAS  Google Scholar 

  • Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de BF, Viale G, Goldhirsch A (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13:73–80

    Article  PubMed  CAS  Google Scholar 

  • Cruz-Munoz W, Man S, Xu P, Kerbel RS (2008) Development of a preclinical model of spontaneous human melanoma CNS metastasis. Cancer Res 68(12):4500–4505

    Article  PubMed  CAS  Google Scholar 

  • Damber JE, Vallbo C, Albertsson P, Lennernas B, Norrby K (2006) The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 58:354–360

    Article  PubMed  CAS  Google Scholar 

  • de Bont ES, Guikema JE, Scherpen F, Meeuwsen T, Kamps WA, Vellenga E, Bos NA (2001) Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin’s lymphoma. Cancer Res 61:7654–7659

    PubMed  Google Scholar 

  • Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E, Colleoni M. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol. 2008;26:4899-905

    Google Scholar 

  • Di Lorenzo G, Autorino R, De Laurentiis M, Forestieri V, Romano C, Prudente A, Giugliano F, Imbimbo C, Mirone V, De Placido S (2007) Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. Cancer Biol Ther 6:313–317

    Article  PubMed  Google Scholar 

  • du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS (2006) Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 12:904–916

    Article  PubMed  Google Scholar 

  • Ellis GK, Livingston RB, Gralow JR, Green SJ, Thompson T (2002) Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol 20:3637–3643

    Article  PubMed  CAS  Google Scholar 

  • Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ, Kerbel RS (2004) A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 64:3994–4000

    Article  PubMed  CAS  Google Scholar 

  • Emmenegger U, Morton GC, Francia G, Shaked Y, Franco M, Weinerman A, Man S, Kerbel RS (2006) Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res 66:1664–1674

    Article  PubMed  CAS  Google Scholar 

  • Emmenegger U, Shaked Y, Man S, Bocci G, Spasojevic I, Francia G, Kouri A, Coke R, Cruz-Munoz W, Ludeman SM, Colvin OM, Kerbel RS (2007) Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. Mol Cancer Ther 6:2280–2289

    Article  PubMed  CAS  Google Scholar 

  • Escuin D, Kline ER, Giannakakou P (2005) Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 65:9021–9028

    Article  PubMed  CAS  Google Scholar 

  • Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967–974

    Article  PubMed  CAS  Google Scholar 

  • Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186

    Article  PubMed  CAS  Google Scholar 

  • Fontana A, Bocci G, Galli L, Fontana E, Galli C, Landi L, Fioravanti A, Orlandi P, Del Tacca M, Falcone A (2007) Low-dose metronomic cyclophosphamide (CTX) plus celecoxib (C) and dexamethasone (DEX) in advanced hormone-refractory prostate cancer (HRPC): A phase II clinical trial with evaluation of clinical and pharmacodynamic effects of the combination. In: ASCO GU Proceedings 2007, abstract 215

    Google Scholar 

  • Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26:76–82

    Article  PubMed  CAS  Google Scholar 

  • Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B (2007) Metronomic cyclophosphamide regimen selectively depletes CD4(+)CD25 (+) regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56: 641–648

    Article  PubMed  CAS  Google Scholar 

  • Gille J, Spieth K, Kaufmann R (2005) Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer. J Dtsch Dermatol Ges 3:26–32

    Article  PubMed  Google Scholar 

  • Glode LM (2006) The case for adjuvant therapy for prostate cancer. J Urol 176:S30–S33

    Article  CAS  Google Scholar 

  • Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R (2003) Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 98:1643–1648

    Article  PubMed  CAS  Google Scholar 

  • Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP (1999) Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 3:147–158

    Article  PubMed  CAS  Google Scholar 

  • Hahnfeldt P, Folkman J, Hlatky L (2003) Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol 220:545–554

    Article  PubMed  Google Scholar 

  • Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, Kalluri R (2004) Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64:1570–1574

    Article  PubMed  CAS  Google Scholar 

  • Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045–1047

    Article  PubMed  CAS  Google Scholar 

  • Haubitz M, Schellong S, Gobel U, Schurek HJ, Schaumann D, Koch KM, Brunkhorst R (1998) Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 41: 1835–1844

    Article  PubMed  CAS  Google Scholar 

  • Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488–498

    PubMed  CAS  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342

    Article  PubMed  CAS  Google Scholar 

  • Jubb AM, Oates AJ, Holden S, Koeppen H (2006) Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 6:626–635

    Article  PubMed  CAS  Google Scholar 

  • Kamen BA, Glod J, Cole PD (2006) Metronomic therapy from a pharmacologist’s view. J Pediatr Hematol Oncol 28:325–327

    Article  PubMed  Google Scholar 

  • Kerbel RS (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21: 505–515

    Article  PubMed  CAS  Google Scholar 

  • Kerbel RS (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312:1171–1175

    Article  PubMed  CAS  Google Scholar 

  • Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–436

    Article  PubMed  CAS  Google Scholar 

  • Kerbel RS, Viloria-Petit A, Klement G, Rak J (2000) ‘Accidental’ anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 36:1248–1257

    Article  PubMed  CAS  Google Scholar 

  • Kieran MW, Turner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, Klement G, Laforme A, Gordon A, Thomas A, Neuberg D, Browder T, Folkman J (2005) A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 27:573–581

    Article  PubMed  Google Scholar 

  • Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15–R24

    Article  Google Scholar 

  • Lam T, Hetherington JW, Greenman J, Maraveyas A (2006) From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials. Anticancer Drugs 17:113–121

    Article  PubMed  CAS  Google Scholar 

  • Lin AM, Ryan CJ, Small EJ (2007) Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol 61: 243–254

    Article  PubMed  Google Scholar 

  • Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, Pandha H (2007) Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 177: 2136–2140; discussion 2140

    Google Scholar 

  • Ma J, Waxman DJ (2007) Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment. Mol Cancer Ther 6:2879–2890

    Article  PubMed  CAS  Google Scholar 

  • Ma J, Waxman DJ (2008) Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther 7:79–89

    Article  PubMed  CAS  Google Scholar 

  • Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS (2002) Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62:2731–2735

    PubMed  CAS  Google Scholar 

  • Mike S, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD (2006) Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev: CD005247

    Google Scholar 

  • Miller KD, Sweeney CJ, Sledge GW Jr (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19:1195–1206

    PubMed  CAS  Google Scholar 

  • Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, Kerbel RS (2006) Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 66:3386–3391

    Article  PubMed  CAS  Google Scholar 

  • Ng SS, Sparreboom A, Shaked Y, Lee C, Man S, Desai N, Soon-Shiong P, Figg WD, Kerbel RS (2006) Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clin Cancer Res 12:4331–4338

    Article  PubMed  CAS  Google Scholar 

  • Nicholson B, Theodorescu D (2004) Angiogenesis and prostate cancer tumor growth. J Cell Biochem 91:125–150

    Article  PubMed  CAS  Google Scholar 

  • Nicolini A, Mancini P, Ferrari P, Anselmi L, Tartarelli G, Bonazzi V, Carpi A, Giardino R (2004) Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother 58:447–450

    PubMed  CAS  Google Scholar 

  • Nishimura K, Nonomura N, Ono Y, Nozawa M, Fukui T, Harada Y, Imazu T, Takaha N, Sugao H, Miki T, Okuyama A (2001) Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer. Oncology 60:49–54

    Article  PubMed  CAS  Google Scholar 

  • Orlando L, Cardillo A, Rocca A, Balduzzi A, Ghisini R, Peruzzotti G, Goldhirsch A, D’Alessandro C, Cinieri S, Preda L, Colleoni M (2006) Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 17:961–967

    Article  PubMed  CAS  Google Scholar 

  • Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

    Article  PubMed  CAS  Google Scholar 

  • Pienta KJ, Smith DC (2005) Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55: 300–318; quiz 323–305

    Google Scholar 

  • Pietras K, Hanahan D (2005) A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23: 939–952

    Article  PubMed  CAS  Google Scholar 

  • Quesada AJ, Nelius T, Yap R, Zaichuk TA, Alfranca A, Filleur S, Volpert OV, Redondo JM (2005) In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ 12:649–658

    Article  PubMed  CAS  Google Scholar 

  • Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Hewitt SM, Shoemaker RH, Melillo G (2004) Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64:6845–6848

    Article  PubMed  CAS  Google Scholar 

  • Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V (2008) Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112:1455–1461

    Article  PubMed  CAS  Google Scholar 

  • Rocca A, Dellapasqua A, Pietri E, Dettori M, D’Alessandro C, Ghisini R, Colombo A, Goldhirsch A, Colleoni M (2007) Metronomic chemotherapy with capecitabine and oral cyclophosphamide in combination with bevacizumab in metastatic breast cancer (mbc): evidence of activity of an antiangiogenic treatment. In: ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18S): abstract 11501

    Google Scholar 

  • Rohan RM, Fernandez A, Udagawa T, Yuan J, D’Amato RJ (2000) Genetic heterogeneity of angiogenesis in mice. Faseb J 14:871–876

    PubMed  CAS  Google Scholar 

  • Ryan CJ, Lin AM, Small EJ (2006) Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol 24:250–253

    PubMed  CAS  Google Scholar 

  • Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D’Amato RJ, Kerbel RS (2005a) Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7:101–111

    PubMed  CAS  Google Scholar 

  • Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313:1785–1787

    Article  PubMed  CAS  Google Scholar 

  • Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, Paraghamian A, Ben-David Y, Kerbel RS (2005b) Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 65:7045–7051

    Article  PubMed  CAS  Google Scholar 

  • Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, Kerbel RS (2005c) Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106:3058–3061

    Article  PubMed  CAS  Google Scholar 

  • Shirakawa K, Furuhata S, Watanabe I, Hayase H, Shimizu A, Ikarashi Y, Yoshida T, Terada M, Hashimoto D, Wakasugi H (2002) Induction of vasculogenesis in breast cancer models. Br J Cancer 87:1454–1461

    Article  PubMed  CAS  Google Scholar 

  • Sterba J, Pavelka Z, Slampa P (2002) Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 49: 117–120

    PubMed  CAS  Google Scholar 

  • Takahashi Y, Mai M, Sawabu N, Nishioka K (2005) A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer. Pancreas 30:206–210

    Article  PubMed  CAS  Google Scholar 

  • Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  PubMed  CAS  Google Scholar 

  • Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764

    PubMed  CAS  Google Scholar 

  • Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS (2002) A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 99:4349–4354

    Article  PubMed  CAS  Google Scholar 

  • Vogelzang NJ (1984) Continuous infusion chemotherapy: a critical review. J Clin Oncol 2:1289–1304

    PubMed  CAS  Google Scholar 

  • Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP (2002) Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 8:349–357

    Article  PubMed  CAS  Google Scholar 

  • Wang J, Lou P, Lesniewski R, Henkin J (2003) Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14:13–19

    Article  PubMed  Google Scholar 

  • Winquist E, Waldron T, Berry S, Ernst DS, Hotte S, Lukka H (2006) Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care’s Genitourinary Cancer Disease Site Group. BMC Cancer 6:112

    Article  PubMed  CAS  Google Scholar 

  • Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, Volpert OV (2005) Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res 11: 6678–6685

    Article  PubMed  CAS  Google Scholar 

  • Young SD, Whissell M, Noble JC, Cano PO, Lopez PG, Germond CJ (2006) Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res 12:3092–3098

    Article  PubMed  CAS  Google Scholar 

  • Zhu AX (2008) Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 112:250–259

    Article  PubMed  CAS  Google Scholar 

  • Cruz-Munoz W, Man S, Kerbel RS. Effective Treatment of Advanced Human Melanoma Metastasis in Immunodeficient Mice Using Combination Metronomic Chemotherapy Regimens. Clin Cancer Res. 2009 Jul 21. [Epub ahead of print]

    Google Scholar 

Download references

Acknowledgments

The work summarized in this review was supported by grants from the National Cancer Institute of Canada, the Canadian Institutes for Health Research, and the National Institutes of Health, USA, to Robert S. Kerbel, and by sponsored research agreements with ImClone Systems, New York, and Taiho Pharmaceuticals, Japan. Urban Emmenegger is supported by the Ontario Institute for Cancer Research through funding provided by the Province of Ontario. We thank Cassandra Cheng for her excellent secretarial assistance.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Medical Oncology, and Department of Medical Biophysics, Division of Molecular and Cellular Biology, Sunnybrook Health Sciences Centre, University of Toronto, 2075, Bayview Avenue, Toronto, ON, Canada, M4N3M5

    Urban Emmenegger

Authors
  1. Urban Emmenegger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giulio Francia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuval Shaked
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert S. Kerbel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Urban Emmenegger .

Editor information

Editors and Affiliations

  1. Medizinische Klinik und Poliklinik A, Universitätsklinikum Münster, Albert-Schweitzer-Str. 33, Münster, 48149, Germany

    Rüdiger Liersch

  2. Medizinische Klinik und Poliklinik, Universitätsklinikum Münster, Albert-Schweitzer-Str. 33, Münster, 48149, Germany

    Wolfgang E. Berdel

  3. Medizinische Klinik und Poliklinik A, Universitätsklinikum Münster, Albert-Schweitzer-Str. 33, Münster, 48149, Germany

    Torsten Kessler

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Emmenegger, U., Francia, G., Shaked, Y., Kerbel, R.S. (2010). Metronomic Chemotherapy: Principles and Lessons Learned from Applications in the Treatment of Metastatic Prostate Cancer. In: Liersch, R., Berdel, W., Kessler, T. (eds) Angiogenesis Inhibition. Recent Results in Cancer Research, vol 180. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-78281-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-78281-0_10

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-78280-3

  • Online ISBN: 978-3-540-78281-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation